<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54501">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396628</url>
  </required_header>
  <id_info>
    <org_study_id>RIG-P000814</org_study_id>
    <secondary_id>2014-004267-20</secondary_id>
    <nct_id>NCT02396628</nct_id>
  </id_info>
  <brief_title>Ruxolitinib In GvHD</brief_title>
  <acronym>RIG</acronym>
  <official_title>Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Graft-versus-Host Disease (GvHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Nikolas von Bubnoff</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Trials Unit Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The preliminary data demonstrate potent activity of Ruxolitinib in steroid-refractory GvHD.
      The investigators therefore intend to launch a clinical phase 2 trial. In this multicenter
      phase 2 trial the investigators will evaluate the efficacy of Ruxolitinib in
      Steroid-refractory acute GvHD in up to 15 transplantation centers. The investigators will
      evaluate the response by monitoring the clinical GvHD grade, requirement of alternative GvHD
      active agents and serum levels of pro-inflammatory cytokines. Until now, there is no report
      of GvHD patients treated with JAK1/2 inhibitors and the investigator don't have the evidence
      for a coexisting trial that investigates the activity of JAK1/2 inhibitors in GvHD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pathophysiological hallmark of GvHD after allo-HCT is an allogeneic donor T cell
      response against recipient antigens. This process is aggravated by increased processing and
      presentation of host antigens by donor APCs following conditioning treatment. The allogeneic
      T cell response leads to inflammation, tissue damage and fibrosis and is mediated by
      extensive production of inflammatory cytokines such as IL-1, IL-2R, IL-6 and TNF. The signal
      transmission of inflammatory cytokines in effector cells (T- cells, macrophages, NK - cells)
      requires activation of specialized kinases from the family of the Janus kinases. These
      kinases, JAK1, 2 and 3 are linked to cytokine receptors, and are activated upon binding of
      the cytokine to the receptor of the inflammatory effector. The JAK1/2 kinase inhibitor
      Ruxolitinib (INC424) is approved for myelofibrosis. In advanced myelofibrosis, Ruxolitinib
      lead to sustained clinical remissions with regard to constitutional symptoms, weight loss
      and spleen size in the majority of treated patients. Of note, clinical responses correlated
      with a marked reduction in inflammatory plasma cytokines.

      Importantly, cytokines down-regulated by Ruxolitinib in patients with myelofibrosis
      correspond to inflammatory effectors that mediate tissue damage and inflammation in GvHD.
      These are mainly the cytokines IL- 1, IL -6, TNF and IFN-γ. Since Ruxolitinib suppresses the
      JAK1 / 2 cytokine response, the investigator hypothesized that Ruxolitinib might attenuate
      the cytokine mediated inflammatory tissue damage in GVHD and thus might favourably affect
      the severity and course of GvHD after allo-HCT.

      In vitro, the investigator demonstrated in an allogeneic system (major mismatch
      mixed-lymphocyte reactions) that co-incubation with Ruxolitinib strongly suppressed both the
      proliferation of allogeneic T cells and the production of inflammatory cytokines. Using a
      very aggressive major mismatch mouse model of acute GvHD (C57BL/6 on BALBc) Ruxolitinib
      treatment significantly prolonged survival of animals. In addition, in these animals showed
      a reduced weight loss, significantly reduced histopathological GvHD severity, suppression of
      inflammatory cytokines in the serum and a reduction of donor T cells in GvHD target organs
      such as the intestines.

      Sole suppression of cytokine production or cytokine receptor activity by Ruxolitinib would
      be very similar to already established drugs for GvHD and no major conceptual advance.
      However the investigator observed that Ruxolitinib did not only suppress cytokine production
      but also led to increased frequencies of FoxP3+ regulatory T cells. This cell type was
      previously shown to lead to long-lasting tolerance as compared to the short-term
      immunosuppression achieved by conventional medication for GvHD.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with response</measure>
    <time_frame>at least four consecutive weeks</time_frame>
    <description>Improvement of at least one stage in the severity of acute GVHD in one organ with-out deterioration in any other organ persisting for at least for four consecutive weeks</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Graft vs Host Disease</condition>
  <arm_group>
    <arm_group_label>Experimental intervetion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Ruxolitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment with Ruxolitinib</intervention_name>
    <description>Treatment with Ruxolitinib at a starting dose of 5 mg BID orally</description>
    <arm_group_label>Experimental intervetion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute skin, intestinal or liver GvHD according to published criteria of the
             International Bone Marrow Transplant Registry (IBMTR) (Cahn, Klein et al. 2005)

          2. Histological confirmation in case of acute intestinal GvHD

          3. Age &gt;18 years

          4. Lack of response to prednisone/prednisolone/methylprednisolone in a dose of at least
             50 mg over at least 7 days prior to screening day

          5. Written informed consent

          6. Ability to understand the nature of the study and the study related procedures and to
             comply with them

        Exclusion Criteria:

          1. Uncontrolled underlying disease

          2. Absence of clinical signs of acute GvHD (Cahn, Klein et al. 2005)

          3. Diagnostic or distinctive clinical signs of chronic GvHD (Filipovich, Weisdorf et al.
             2005)

          4. Uncontrolled bacterial, viral or fungal infection

          5. Active CMV infection as demonstrated by serum CMV DNA copies of 1500 copies/mL or
             higher

          6. Absolute neutrophil count &lt; 0.5 G/l

          7. Platelet count &lt; 50 G/L

          8. Any previous JAK2 inhibitor treatment prior to study enrolment, with the exception of
             Ruxolitinib

          9. Known Hypersensitivity to Ruxolitinib

         10. Known positivity for HIV, Hepatitis B or Hepatitis C at the time of screening.

         11. Female patients who are pregnant or breast feeding

         12. Concomitant use of any other investigational drug within the last thirty days before
             the start of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nikolas von Bubnoff, Professor</last_name>
    <phone>+49 761 270-</phone>
    <phone_ext>33210</phone_ext>
    <email>nikolas.bubnoff@uniklinik-freiburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Zeiser, Professor</last_name>
    <phone>+49 761 270-</phone>
    <phone_ext>36250</phone_ext>
    <email>robert.zeiser@uniklinik-freiburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Il-Kang Na, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Hemmati, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dominik Wolf, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annkristin Heine, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Friedrich Stölzel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rainer Ordemann, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Markus Ditschkowski, PD Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nina Steckel,, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nikolas von Bubnoff, Professor</last_name>
      <email>nikolas.bubnoff@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Nikolas von Bubnoff, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Zeiser, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francis Ayuk, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dietlinde Janson, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Peter Dreger, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Luft, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum München TU rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mareike Verbeek, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Grass, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Götz Grigoleit, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Mielke, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 11, 2016</lastchanged_date>
  <firstreceived_date>March 10, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Freiburg</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Nikolas von Bubnoff</investigator_full_name>
    <investigator_title>Coordinating Investigator</investigator_title>
  </responsible_party>
  <keyword>Graft-versus-Host Disease (GvHD)</keyword>
  <keyword>resistance to therapy</keyword>
  <keyword>allogeneic stem cell transplantation</keyword>
  <keyword>Ruxolitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
